Preview

Злокачественные опухоли

Расширенный поиск

Обзор новых исследований, способных изменить клиническую практику при раке поджелудочной железы

Полный текст:

Аннотация

.

Об авторе

И. А. Покатаев
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Министерства здравоохранения РФ.
Россия


Список литературы

1. Покатаев И. А., Алиева С. Б, Гладков О. А., Загайнов В. Е., Кудашкин Н. Е., Патютко Ю. И. и соавт. Практические рекомендации по лекарственному лечению рака поджелудочной железы // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2017 (том 7). С. 367–379.

2. Varadhachary G. R., Tamm E. P., Abbruzzese J. L. et al. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy // Annals of Surgical Oncology. – 2006. – V 13, N 8. – P. 1035–1046.

3. Yamada S., Fujii T., Sugimoto H., et al. Aggressive surgery for borderline resectable pancreatic cancer: Evaluation of National Comprehensive Cancer Network guidelines. // Pancreas. – 2013. – V. 42. – P. 1004–1010.

4. Laurence J.M., Tran P.D., Morarji K. al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. // J Gastrointest Surg. – 2011. – V. 15, N 11. – P. 2059–69.

5. Van Tienhoven G., Versteijne E., Suker M. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. // Journal of Clinical Oncology. – 2018. – V. 36, N 18_suppl. – LBA4002.

6. Jang J. Y., Han Y., Lee H. et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. // Ann Surg. –2018. – V. 268, N 2. – P. 215–222.

7. Reni M., Balzano G., Zanon S. et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. // Lancet Gastroenterol Hepatol. – 2018. – Published Online April 3, 2018.

8. Hartman D. J., Krasinskas A. M. Assessing treatment effect in pancreatic cancer. // Arch Pathol Lab Med. – 2012. – V. 136. – P. 100–09.

9. Hammel P., Huguet F., Van Laethem J. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial // JAMA. – 2016. – V. 315, N 17. – P. 1844–1853.

10. Klaassen D. J., MacIntyre J. M., Catton G. E. et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. // J Clin Oncol. – 1985. – V. 3. – P. 373–378.

11. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. // J Natl Cancer Inst. – 1988. – V. 80. – P. 751–755.

12. Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCDSFRO study. // J Clin Oncol – 2006. – V. 24 (Suppl 18). – A-4008, P. 180s.

13. Loehrer P. J. Sr, Feng Y., Cardenes H. et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. // J Clin Oncol. – 2011. –V. 29, N 31. – P. 4105–12.

14. Neoptolemos J., Palmer D., Ghaneh P. et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. // J Clin Oncol. – 2016. – V. 34 (suppl). – LBA4006.

15. Neoptolemos J.P., Stocken D.D., Friess H. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. // N Engl J Med – 2004. – V. 350. – P. 1200–10.

16. Neoptolemos J.P., Moore M.J., Cox T.F. et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. // JAMA. – 2012. – V. 308, N 2. – P. 147–56.

17. Oettle H., Neuhaus P., Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. // JAMA. – 2013. – V. 310, N 14. – P. 1473–81.

18. Conroy T., Hammel P., Hebbar M. et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. // Journal of Clinical Oncology – 2018. – V. 36, N 18_suppl. – LBA 4001.

19. Hall B.R., Cannon A., Atri P. et al. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. // Oncotarget. – 2018. – V. 9, N 27. – P. 19396–19405.

20. Nagriala A.M., China V.T., Sjoquistc K.M. et al. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials // Critical Reviews in Oncology/Hematology. – 2015. –V. 96. – P. 483–497.

21. Dahan L., Phelip J.M., Le Malicot K. et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). // Journal of Clinical Oncology. – 2018. –V. 36, N 15_suppl. – P. 4000.

22. NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma, v 2.2018. Published online 10.07.2018. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf .

23. Maitra A., Hruban R.H. Pancreatic cancer. // Annu Rev Pathol. – 2008. – V. 3. – P. 157–188.

24. Jones S., Zhang X., Parsons D.W. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. // Science. – 2008. – V. 321. – P. 1801–1806.

25. Hidalgo M. Pancreatic cancer. // N Engl J Med. – 2010. – V. 362. – P. 1605–1617.

26. Pishvaian M.J., Bender R.J., Halverson D. et al. Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative. //–Clin Cancer Res. – 2018. – In print

27. Frogne T., Laenkholm A.V., Lyng M.B. et al. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. // Breast Cancer Res. – 2009. – V. 11. – P. R11.

28. Wulfkuhle J.D., Berg D., Wolff C. et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. // Clin Cancer Res. – 2012. – V. 18. – P. 6426–35.


Для цитирования:


Покатаев И.А. Обзор новых исследований, способных изменить клиническую практику при раке поджелудочной железы. Злокачественные опухоли. 2018;(3s1):76-81.

For citation:


. . Malignant tumours. 2018;(3s1):76-81. (In Russ.)

Просмотров: 71


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)